Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer

Award Number: R42CA272056
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/09/2022
PERIOD OF PERFORMANCE END DATE: 11/30/2024

Group Awards By:

View Award Description

Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer - ABSTRACT Prostate cancer, rather indolent by nature, has specific subtypes present with aggressive locoregional disease that are quickly becoming hormonal resistant. Patients with castrate-resistant disease (CRPC) are generally younger and non-Caucasian, and many suffer from local progression, edema, and pain. Radiotherapy (RT) is offered but limited by the extent, former exposure, and resistance of disease. Sequential multiple chemotherapy or RT treatments, offered as standard of care, are hard to comply to, especially in low-resource populations. Treatment of this symptomatic population is often terminated prematurely, or never started, due to financial and time restrictions. Innovative, shorter more efficient treatments are needed, especially to reduce disparities in compliance and outcomes of global cancer care. In extensive preclinical work, the combination of RT with immunogenic smart radiotherapy materials (iSRBs), addressed as radio-immunotherapy dose-painting (RAID) technology, brings intra-tumoral slow-release antiCD40 payload in the target that gets irradiated and has shown to prime the immune system and create sustainable tumor control by in situ-vaccination, even after different therapeutic options have failed. Moreover, this combination treatment can improve quality of life (QoL) fast by a short simple intervention with fewer side effects, having an antiCD40 payload far smaller than needed in intravenous (IV) immunotherapy. The overall goal of this project - proposed by Nanocan Therapeutics Corporation in collaboration with John Hopkins Medicine, Dana-Farber Cancer Institute and Northwell Health - is to bridge preclinical work to the first clinical trial with the innovative RAID technology and confirm its potential for in situ-vaccination that can extend the use of radiotherapy (RT) from palliative local treatment to systemic disease control in one session. The iSRBs are as seed-like fiducial markers administered directly in the prostate tumor by ultrasound guided needles. The iSRBs create contrast on CT and KV imaging making RT set-up fast; iSRBs slowly release (20mcg per unit over 15 days) anti-CD40 payload directly the target which gets irradiated, triggering in situ-vaccination. The purpose of this project is to translate extensive safety and efficacy data from small animal studies of single fraction RT combined with slow released intra-tumoral antiCD40 delivery to a first human trial for CRPC patients. The first part will be used to optimize iSRBs into a cGMP product, and confirmation of larger volume testing in monkeys to confirm safety, immunogenicity, and pharmacokinetics already performed in extensive small animal work. Milestones will complete IND filling by Nanocan Therapeutics. After FDA approval, second part of the project will encompass the Phase 1 single arm open label clinical trial seeking confirmation of safety and number of iSRBs as well as RT dose needed in CRPR patients. This project can provide all needed data for planned Phase II clinical work in aims offering a novel treatment paradigm for CRPR patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	NANOCAN THERAPEUTICS CORPORATION	137 NATIONAL PLZ STE 300	NATIONAL HARBOR	MD	20745	PRINCE GEORGES	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	3/26/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	NANOCAN THERAPEUTICS CORPORATION	900 NEW HAMPSHIRE AVE NW	WASHINGTON	DC	20037	DISTRICT OF COLUMBIA	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	11/15/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	NANOCAN THERAPEUTICS CORPORATION	103 CARNEGIE CTR STE 300	PRINCETON	NJ	08540	MERCER	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	11/21/2022	NEW	$0
2023	2022	NANOCAN THERAPEUTICS CORPORATION	103 CARNEGIE CTR STE 300	PRINCETON	NJ	08540	MERCER	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	1	12/5/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $399,680 )
2022	2022	NANOCAN THERAPEUTICS CORPORATION	103 CARNEGIE CTR STE 300	PRINCETON	NJ	08540	MERCER	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	1	5/11/2022	NEW	$0
2022	2022	NANOCAN THERAPEUTICS CORPORATION	103 CARNEGIE CTR STE 300	PRINCETON	NJ	08540	MERCER	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	002	1	9/12/2022	NEW	$0
2022	2022	NANOCAN THERAPEUTICS CORPORATION	103 CARNEGIE CTR STE 300	PRINCETON	NJ	08540	MERCER	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	5/6/2022	NEW	$399,680
														Subtotal = $399,680

Grand Total All Awards = $399,680

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer

Award Number: R42CA272056

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/09/2022

PERIOD OF PERFORMANCE END DATE: 11/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer